Cellens

Decision/Risk Analysis · Boston, MA · Founded 2019 · Privately Held (backing)

Developer of a cell surface scanning platform designed to assist oncologists in performing noninvasive detection of bladder cancer. Cellens is based in Boston, MA and was founded in 2019. It was valued at $19.4 million at its early-stage round in Aug 2025, the last priced event on record. It has raised $7.5 million across 3 recorded rounds; the latest was a $6.4 million early-stage round in Aug 2025.

PMV mark · valuation
$19.4M
Oct 2026
Priced at
its early-stage round
Aug 2025
Total raised
$7.5M
Last round
Early Stage VC
Aug 2025

Who backs Cellens?

19 investors
InvestorType
Creative Destruction LabOther
SOSVVenture capital
Springboard EnterprisesOther
IndieBioOther
VentureWellOther
Labcorp Venture FundVenture capital
TiE Angels BostonVenture capital
ACS BrightEdge—
Blackwood Healthcare Breakthroughs—
C2I Accelerator—
+ 9 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Cellens investors

19 investors are on record for Cellens, including Creative Destruction Lab, SOSV, Springboard Enterprises and IndieBio. The early-stage round in Aug 2025 drew 33 investors.

Free account
More of Cellens with a free account
  • ·The complete investor list: 19 names
  • ·Watch Cellens: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 19 firms already write checks for companies like Cellens in decision/risk analysis. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View